AIM ImmunoTech announced availability of ME/CFS clinical trial of drug Ampligen for enrollment to COVID-19 ムLong Haulersメ
On Dec. 24, 2020, AIM ImmunoTech announced that the post-COVID-19 モLong Haulerヤ portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment.
Eligible patients enrolled in the trial receive treatment with AIMメs flagship pipeline drug Ampligen.
Tags:
Source: AIM ImmunoTech
Credit: